Fluticasonfuroat bør kun anvendes i ammeperioden, hvis fordelene for moderen opvejer de eventuelle risici for barnet.
Administration of fluticasone furoate to women who are breastfeeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.